RxDoctor Payments Data

Jose Jimenez, MD

Gastroenterology · San Juan, PRNPI 1508851049

Payments from drug & device makers

$3,622in general payments, 2019–2025

Across 157 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$449
  • PBG Puerto Rico LLC$279
  • Takeda Pharmaceuticals U.S.A., Inc.$111
  • Exact Sciences$25
  • plus $82 from 4 others

What the payments were for

  • Food & beverage$3,52397%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie69$1,634
Johnson & Johnson(2 entities)42$1,041
E.r. Squibb & Sons, L.L.C.21$449
PBG Puerto Rico LLC14$279
Takeda Pharmaceuticals U.S.A., Inc.6$111
Exact Sciences1$25
Merck1$23
Organon1$20
Gilead1$20
Pfizer Pharmaceuticals LLC1$19

How this compares

$3,622 in reported general payments places this provider in the 65th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$26,912
Medicare patients
87
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sucralfate508$73,252
Dexlansoprazole DrDexlansoprazole139$28,338
CreonLipase/Protease/Amylase38$23,719
DexilantDexlansoprazole32$11,602
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates137$10,749
SuprepSodium, Potassium,mag Sulfates81$9,555
Mesalamine DrMesalamine18$6,688
Entecavir19$5,352
Mesalamine14$5,173
Lubiprostone30$4,129
Pantoprazole Sodium433$4,075
NexiumEsomeprazole Magnesium12$3,358
Ursodiol27$2,118
Omeprazole199$1,614
Esomeprazole Magnesium75$1,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$1,634$23,71938 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$111$11,60232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →